Structural basis of transcription inhibition by fidaxomicin (lipiarmycin A3)

Fidaxomicin is an antibacterial drug in clinical use for treatment of Clostridium difficile diarrhea. The active ingredient of fidaxomicin, lipiarmycin A3 (Lpm), functions by inhibiting bacterial RNA polymerase (RNAP). Here we report a cryo-EM structure of Mycobacterium tuberculosis RNAP holoenzyme...

Full description

Bibliographic Details
Main Authors:	Lin, W, Das, K, Degen, D, Mazumder, A, Duchi, D, Wang, D, Ebright, Y, Ebright, R, Sineva, E, Gigliotti, M, Srivastava, A, Mandal, S, Jiang, Y, Liu, Y, Yin, R, Zhang, Z, Eng, E, Thomas, D, Donadio, S, Zhang, H, Zhang, C, Kapanidis, A
Format:	Journal article
Language:	English
Published:	Cell Press 2018

Structural basis of transcription inhibition by fidaxomicin (lipiarmycin A3)

Similar Items